Seroprevalence of Human T-cell Lymphotropic Virus Types I/II Among Blood Donors in a Tertiary Hospital in Oman

• Published in: Oman medical journal Vol. 39; no. 1; pp. 1 - 5
• Main Authors: Al-Bulushi, Noora, Al Maamari, Khuloud, Ba Alawi, Fatma, Al-Riyami, Arwa Z., Al Marhoobi, Ali
• Format: Journal Article
• Language: English
• Published: Muscat, Oman Oman Medical Specialty Board 01.01.2024; OMJ
• Subjects: Blood donors; Data processing; Economic conditions; HTLV-I (Virus); HTLV-II (Virus); human t-lymphotropic virus 1; human t-lymphotropic virus 2; oman; Original; seroepidemiologic studies; University hospitals; Seroepidemiologic Studies; Human T-lymphotropic virus 1; Oman; Human T-lymphotropic virus 2
• ISSN: 1999-768X; 2070-5204
• DOI: 10.5001/omj.2024.42

Objectives: Routine blood donor screening of human T-cell lymphotropic virus (HTLV) has been practiced in Oman since 2017. Limited data exists on HTLV seroprevalence among Omanis. This study aims to determine the seroprevalence of HTLV-I/II among blood donors attending a hospital-based blood bank to assess the need for a universal versus targeted screening. Methods: We conducted a retrospective review of blood donors' results attending a hospital blood bank between January 2017 and February 2020. Blood samples were screened for HTLV-I/II antibodies using ARCHITECT i2000SR. Reactive samples underwent further testing by immunoblot assay (MP Diagnostics HTLV Blot 2.4). Age, gender, and nationality were assessed. All components manufactured at the blood bank undergo leukoreduction before storage. Results: A total of 24 469 firsttime blood donors were screened for HTLV antibodies. Most participants were male (n equivalent 22 186, 90.7%), and the majority were Omani (n equivalent 22 711, 92.8%). The age range was 18 to 64 years, with a median of 32 years. The seroreactivity rate was 0.2% (43; 95% CI: 0.12-0.23). Confirmatory testing by immunoblot revealed three indeterminate results (7.9%), of which two were Omani and one non-Omani donor, and the remaining 40 seroreactive donors tested negative. Conclusions: Our study revealed zero seroprevalence of confirmed HTLV among blood donors. The continuation of universal screening for first-time donors is a standard of care. With universal leukoreduction at Sultan Qaboos University Hospital and a very low risk of HTLV in Oman's population, the need for screening regular donors can be reconsidered if these findings are confirmed on a larger scale involving other blood banks in Oman.